Giant nonfunctioning adrenocortical carcinoma: a case report and review of the literature

BMC Research Notes

Saad Aldousari⁴  Adel Al-Hunayan⁴  Sundus Hussain¹  Sami Asfar³  Ahmad Almarzouq² 

[1] Department of Pathology, Mubarak Alkabeer Hospital, Kuwait City, Kuwait;Urology Unit, Department of Surgery, Mubarak Alkabeer Hospital, Kuwait City, Kuwait;Department of Surgery, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait;Urology Unit, Department of Surgery, Faculty of Medicine, Kuwait University, PO Box 24923, Safat 13110, Kuwait

关键词: Nonfunctioning;    Giant;    Adrenocortical mass;    Adrenocortical carcinoma;   

Others  :  1125780
DOI  :  10.1186/1756-0500-7-769

 received in 2014-05-06, accepted in 2014-10-18,  发布年份 2014

【 摘 要 】

Background

Adrenocortical carcinoma is a rare and aggressive malignancy. Patients usually present early with manifestation of abnormal hormone secretion. However, adrenocortical carcinoma can also be nonfunctioning, and such patients present late with a mass effect or distant metastases.

Case presentation

We herein report a case of a 30-year-old Sri-Lankan woman who presented with a 3-month history of left flank pain associated with nausea, vomiting, and weight loss. Imaging revealed a large left upper quadrant mass with a 1.8-cm left lung nodule. The differential diagnoses included a left adrenal mass, left upper pole renal mass, and retroperitoneal sarcoma. A functional adrenal work-up revealed no abnormal findings. Surgical excision of the mass was uneventful with no postoperative complications. Pathological analysis revealed a nonfunctioning adrenocortical carcinoma measuring 16 × 14 × 10 cm. To our knowledge, a mass of this size is among the largest nonfunctioning adrenocortical carcinomas reported in the published literature. The investigations and approach to treatment were consistent with those in the published literature.

Conclusion

Large nonfunctioning adrenocortical carcinomas pose a diagnostic and therapeutic challenge, and most are diagnosed at a late stage. Appropriate imaging and functional work-up of the mass are vital before treatment. Surgical excision is safe, even for large adrenocortical carcinomas; excision in patients with advanced disease has been shown to have the best outcomes.

【 授权许可】

   
2014 Almarzouq et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Norton JA: Adrenal tumors. In Cancer: Principles and Practice of Oncology. 7th edition. Edited by DeVita VTJr, Hellman S, Rosenberg SA. Philadelphia, PA: Lippincott Williams Wilkins; 2005:1528-1539.
• [2]Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C: Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001, 25:891-897.
• [3]Kopf D, Goretzki PE, Lehnert H: Clinical management of malignant adrenal tumors. J Canc Res Clin Oncol 2001, 127(3):143-155.
• [4]Gaujoux S, Al-Ahmadie H, Allen PJ, Gonen M, Shia J, Dángelica M, Dematteo R, Fong Y, Jamagin WR: Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol 2012, 19:2643.
• [5]Kemp C, Ripley R, Mathur A, Steinburg SM, Nguyen DM, Fojo T, Schrump DS: Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience. Ann Thorac Surg 2011, 92(4):1195-1200.
• [6]Vassilopoulou-Sellin R, Schultz PN: Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001, 92:1113.
• [7]Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Hebra MA: Adrenocortical Carcinoma: Clinical Outcomes and prognosis of 330 Patients at a Tertiary Care Center. Eur J Endocrinol 2013, 169:891-899.
• [8]Schulick RD, Brennan MF: Long-Term Survival After Complete Resection and Repeat Resection in Patients With Adrenocortical Carcinoma. Ann Surg Oncol 1999, 6:719-726.
• [9]Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP: Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005, 12:667.
• [10]Norton J, Le H: Adrenal tumors. In Cancer. 6th edition. Edited by DeVita VT. Philadelphia: Lippincott Williams & Wilkins; 2001:1770-1785.
• [11]Deandreis D, Leboulleux S, Caramella C, Schlumberger M, Baudin E: FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011, 2:354.
• [12]Weiss LM: Comperative histologic study of 43 metastasizing and non metastasizing adrenocortical tumors. Am J Surg Pathol 1984, 8:163-169.
• [13]Tseng Y: Wu s, Chao, Wu C J, Chau T. International Journal of Nephrology: Yang S S. A Giant Non-Functional Adrenocortical Carcinoma Presenting With Acute Kidney Injury; 2013. doi:10.1007/s11255-013-0629-2
• [14]Kapoor A, Morris T, Rebello R: Guidelines for the Management of the Incidentally Discovered Adrenal Mass. Can Urol Assoc J 2011, 5(4):241-247.
• [15]National Institutes of Health: “NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consensus and State-of-the-Science Statements 2002, 19:1-25. no. 2
• [16]Benassai G, Desiato V, Bianco T, Seviro L, Compagna R, Vigliotti G, Limite B, Quatro G: Adrenocortical carcinoma: What the surgeon needs to know. Case report and literature review. Int J Surg 2014, 12S1:S22-S28. doi:10.1016/j.ijsu.2014.05.030